A part 1 trial evaluating SENTI-202 demonstrated optimistic preliminary leads to treating relapsed/refractory acute myeloid leukemia.Constructive preliminary information from a part 1 scientific...
The Ventana TROP2 RxDx System, an AI-powered diagnostic software, acquired FDA breakthrough standing to be used in non–small cell lung most cancers.The Ventana...
TAR-200 led to an 82.4% full response price in BCG-unresponsive, high-risk non-muscle invasive bladder most cancers with CIS, knowledge from SunRISe-1 confirmed.Amongst sufferers...
